Lanean...
GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors
Mutant KRas is a significant driver of human oncogenesis and confers resistance to therapy, underscoring the need to develop approaches that disable mutant KRas-driven tumors. Because targeting KRas directly has proven difficult, identifying vulnerabilities specific for mutant KRas tumors is an impo...
Gorde:
| Argitaratua izan da: | Nat Commun |
|---|---|
| Egile Nagusiak: | , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Nature Publishing Group UK
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6279809/ https://ncbi.nlm.nih.gov/pubmed/30514931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-07644-6 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|